{"id":25160,"date":"2025-11-17T08:57:05","date_gmt":"2025-11-17T13:57:05","guid":{"rendered":"https:\/\/medicarereport.org\/?p=25160"},"modified":"2025-11-17T08:57:07","modified_gmt":"2025-11-17T13:57:07","slug":"fdas-plan-to-boost-biosimilar-drugs-could-stall-at-the-patent-office","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=25160","title":{"rendered":"FDA\u2019s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office"},"content":{"rendered":"\n

(By Arthur Allen for KFF Health News)<\/p>\n\n\n\n

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the cheaper medicines to get on the market, industry officials say.<\/p>\n\n\n\n

These officials were thrilled Oct. 29 when FDA Commissioner Marty Makary announced the agency\u2019s plan, which he said would halve the time and money needed to get what are called \u201cbiosimilar\u201d drugs to market. Biosimilars are essentially generic versions of biologics \u2014 such as Humira, Keytruda, and Xolair \u2014 which are made from living organisms. Biosimilars can cost up to 90% less. Continue reading here…<\/a><\/p>\n\n\n\n

Kaiser Health News is a nonprofit national health polity news service that is part of the nonpartisan Henry J. Kaiser Family Foundation<\/p>\n\n\n\n

\"\"<\/p>\n\n\n\n

Notice:<\/strong>\u00a0The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n","protected":false},"excerpt":{"rendered":"

(By Arthur Allen for KFF Health News) While the FDA is streamlining regulation of copycat versions of the expensive drugs<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31,21,20,15],"tags":[428,76,385,238,65],"class_list":["post-25160","post","type-post","status-publish","format-standard","hentry","category-fda","category-health-care-finance","category-health-care-redesign","category-part-dprescription-drugs","tag-biosimilars-drugs","tag-fda","tag-healthcare-costs","tag-healthcare-finance","tag-medicare-part-d"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/25160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25160"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/25160\/revisions"}],"predecessor-version":[{"id":25161,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/25160\/revisions\/25161"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}